{"id":"masked-oral-valacyclovir","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Tremor (at high doses)"}]},"_chembl":{"chemblId":"CHEMBL1349","moleculeType":"Small molecule","molecularWeight":"324.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valacyclovir is a prodrug that is converted to acyclovir in the body. Acyclovir is phosphorylated by viral thymidine kinase and then inhibits viral DNA polymerase, preventing viral DNA synthesis and replication. The masking technology improves palatability for oral administration, particularly in pediatric populations.","oneSentence":"Masked oral valacyclovir is a taste-masked formulation of valacyclovir that inhibits viral DNA polymerase to prevent herpes simplex virus and varicella-zoster virus replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:58.897Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Herpes simplex virus infection (oral and genital herpes)"},{"name":"Varicella-zoster virus infection (chickenpox and shingles)"},{"name":"Cytomegalovirus prophylaxis in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT03134196","phase":"PHASE4","title":"Zoster Eye Disease Study","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2017-08-23","conditions":"Herpes Zoster Ophthalmicus","enrollment":527},{"nctId":"NCT00587496","phase":"PHASE1","title":"30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers","status":"UNKNOWN","sponsor":"National Eye Institute (NEI)","startDate":"2006-04","conditions":"Herpes Simplex","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Valtrex"],"phase":"marketed","status":"active","brandName":"Masked Oral Valacyclovir","genericName":"Masked Oral Valacyclovir","companyName":"NYU Langone Health","companyId":"nyu-langone-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Masked oral valacyclovir is a taste-masked formulation of valacyclovir that inhibits viral DNA polymerase to prevent herpes simplex virus and varicella-zoster virus replication. Used for Herpes simplex virus infection (treatment and suppression), Varicella-zoster virus infection (chickenpox and shingles).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}